View More Recent Stories
-
Roivant Sciences (ROIV) Announces Positive Results for Batoclimab Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Studies
-
Genevant Sciences (ROIV) and Arbutus Biopharma (ABUS) Initiate International Patent Infringement Enforcement Actions Against Moderna
-
Roivant Sciences Ltd. (ROIV) Tops Q3 EPS by 48c
-
Roivant Sciences (ROIV) 30K contracts of January 15 2026 calls
-
Increasing unusual option volume: EIX INVZ ROIV PCG CHAU NVT SENS OPFI GRRR HPP
-
Roivant Sciences (ROIV) spreader of 15K contracts of February 10 puts and February 11 calls
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
Roivant Sciences Ltd. (ROIV) Misses Q2 EPS by 2c
-
Organon (OGN) Completes Acquisition of Dermavant
-
Leerink Partners Reiterates Outperform Rating on Roivant Sciences (ROIV)
-
JPMorgan Reiterates Overweight Rating on Roivant Sciences (ROIV), 'ROIV is on the Analyst Focus List'
-
Roivant Sciences (ROIV) 5K contracts of October 12 calls trade
-
Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)
-
H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
-
TD Cowen Reiterates Buy Rating on Roivant Sciences (ROIV)
-
Organon (OGN) to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA Cream, 1%
-
TD Cowen Reiterates Buy Rating on Roivant Sciences (ROIV)
-
H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
-
Roivant Sciences (ROIV) PT Raised to $12.50 at BofA Securities
-
Roivant Sciences (ROIV) Unveils New Pipeline Program Mosliciguat
-
Roivant Sciences (ROIV) presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat
-
Roivant Sciences (ROIV) Provides Update on Graves’ Disease Development Program
-
Increasing unusual call option volume: ROIV NEXT URBN DG SBLK NCNO GPRE CAMT VUZI
-
Increasing unusual option volume: ROIV GLNG PTEN DINO NBR NGD PRGO
-
H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
-
Roivant Sciences (ROIV) spreaders active in September 10 puts, September 11 and 12 calls
-
Roivant Sciences Ltd. (ROIV) Tops Q1 EPS by 36c
-
Piper Sandler Reiterates Overweight Rating on Roivant Sciences (ROIV)
-
Roivant Sciences (ROIV) PT Raised to $22 at Piper Sandler

